Print Magazine
Brussels Morning Newspaper
Monday, June 5, 2023
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home Europe

EU drugs regulator finds no evidence against AstraZeneca shot

Nikola Kiš by Nikola Kiš
1 April 2021
in Europe
shutterstock_1918293236

A medical staff inoculates a woman with the AstraZeneca COVID-19 vaccine

Share on FacebookShare on Twitter

Brussels (Brussels Morning) The European Medicines Agency (EMA) has said there is no scientific evidence to support restricting the use of the COVID-19 vaccine developed by British-Swedish AstraZeneca at this time, DW reported on Wednesday.

EMA Executive Director Emer Cooke pointed out that the agency will continue looking into reports of blood clots, but reiterated that EMA has not found a causal link between the vaccine and blood clots.

“According to the current scientific knowledge, there is no evidence that would support restricting the use of this vaccine in any population,” Cooke concluded.

Some have imposed restrictions 

Germany suspended the use of the AstraZeneca shot in March, only to lift the suspension for some age groups later on.

Several EU member states have temporarily halted the use of the shot for some age groups, citing the risk of blood clots.

According to EMA’s data, rare blood clots occurred in 4.8 cases per million AstraZeneca shots administered. This compared to 0.2 cases per million for Pfizer-BioNTech and zero for Moderna. In the case of the latter, EMA suggested this was likely because the Moderna vaccine is not widely used in Europe.

However, Thomas Mertens, chair of the German Standing Committee on Vaccination at the Robert Koch Institute, maintains that the age group restriction was necessary. “We have our own very solid data on this point,” he said, while noting that he was “not at all happy about this decision” even though, given the available data, it was necessary.

Mertens pointed out that doses would be reassigned from one group to another, saying he hoped the move would not significantly affect the country’s vaccination campaign.

Germany reported 31 blood clot cases in the week up to 29 March, representing a 100% increase compared to the period up to 22 March.

EMA noted it found 62 such cases worldwide in the period up to 22 March.

Tags: Main-Slider
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • Health & Fitness
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • Brussels Bubble
    • Parliament
    • Commission
    • Council
  • Wider Europe
    • Member States
  • World
  • Business & Society
  • Europe With Transparency
  • Culture & Society
  • Policy Talks
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • Ambassador’s Corner
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT